Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... The drug has got off to a flying start in the US market, achieving rapid uptake since its launch in April, despite ...

Students who have accepted their offer of admission for Fall 2025 may request to switch to Early Start by submitting the “Early Start” form under the Reply Forms tab in their admissions application ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Below is a list of the most common questions we receive in our office. If you do not see your question, please feel free to visit our Contact Page and reach out directly. Purdue Early Start is an ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

After hours: February 7 at 7:10:49 PM EST Loading Chart for FORM ...

Dupixent, Adbry, and Ebglyss are FDA-approved only for the atopic dermatitis form of eczema. It is possible, however, that healthcare providers might also prescribe these medicines off-label for other ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals' ...